See the DrugPatentWatch profile for Dupilumab
Dupilumab, marketed under the brand name Dupixent, is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [1][2][3]. The price of Dupixent can vary significantly based on factors such as insurance coverage, geographic location, and the specific dosage and treatment duration [4].
How much does Dupixent typically cost?
Without insurance, the list price for a two-pen supply of Dupixent (which typically lasts for one month of treatment) can range from approximately $3,700 to $4,000 [4][5]. However, patient assistance programs and insurance formularies can substantially reduce out-of-pocket expenses for eligible individuals [4].
What assistance programs are available for Dupixent?
Sanofi, the manufacturer of Dupixent, offers patient support programs, including co-pay assistance for commercially insured patients [6]. These programs can help lower the cost for eligible patients to as little as $10 per prescription fill, up to a yearly maximum [4][6]. Uninsured or underinsured patients may also qualify for free medication through specific programs, provided they meet certain criteria [4].
When does Dupixent's patent expire?
The patent landscape for Dupixent is complex, with multiple patents covering different aspects of the drug, including its formulation and methods of use [7]. As of recent information, key patents for Dupixent are expected to expire at various times, with some expiring around 2030 and others later [7]. These patent expirations are relevant to the potential development of biosimilar versions of Dupixent in the future [8].
Are there alternatives to Dupixent?
Several other medications are available for treating atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, depending on the severity and specific patient profile. These may include topical corticosteroids, calcineurin inhibitors, JAK inhibitors, and other biologic agents. The choice of treatment often depends on individual patient needs, response to therapy, and physician recommendation [9][10].
What is the mechanism of action for Dupixent?
Dupixent is a monoclonal antibody that inhibits the signaling of two key cytokines, IL-4 and IL-13, which play a central role in Type 2 inflammation [1][2][3]. By blocking these pathways, Dupixent helps to reduce inflammation associated with conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [1][2][3].
Where can I find more information on Dupixent pricing and availability?
For detailed and up-to-date information regarding the cost of Dupixent, including patient assistance programs and potential out-of-pocket expenses, consulting the official Dupixent website or contacting the manufacturer directly is recommended. DrugPatentWatch.com provides insights into the patent status of medications like Dupixent, which can be relevant for understanding future market dynamics and the potential introduction of generics or biosimilars [7][8].
Sources:
[1] https://www.dupixent.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045172/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1714710
[4] https://www.goodrx.com/dupixent
[5] https://www.healthline.com/health/dupixent-cost
[6] https://www.dupixent.com/dupixent-savings-and-support
[7] https://drugpatentwatch.com/
[8] https://drugpatentwatch.com/blog/understanding-biosimilar-patents-and-exclusivity
[9] https://www.mayoclinic.org/diseases-conditions/atopic-dermatitis-eczema/diagnosis-treatment/drc-20353276
[10] https://www.ginasthma.org/wp-content/uploads/2022/07/GINA-Report-2022-final-wms.pdf